36 corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of DVT were 2.5%, 3.6% and 8.3% respectively, while the incidences in patients receiving the recommended regimen of UFH in the treatment of PE were 5.5%, 6.6% and 7.4%, respectively.
Analoogseid veritsusjuhtumeid enoxapariini soovitatud annustes SVT raviks saanud patsientidel olid 2, 5%; 3, 6% ja 8, 3% ja mittefraktsioneeritud hepariini PE raviks soovitatud annustes saanud patsientidel oli 5, 5%; 6, 6% ja 7, 4% vastavalt.